All In Biotech

Drug Trial Radar · NCT02060383

Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly

Last checked: Nov 20, 2026Latest source record: May 29, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 249 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

249

Actual

Start

May 23, 2014

Primary completion

Feb 5, 2018

Study completion Mar 26, 2018

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 12, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study was designed to investigate the optimal management of hyperglycemia developed during pasireotide treatment in participants with Cushing's disease or Acromegaly, which was not manageable with metformin. This was a Phase IV, multi-center, randomized, open-label study. Eligible patients started pasireotide subcutaneously (s.c.) for Cushing's disease and pasireotide LAR (long-acting release) for Acromegaly. Participants being treated with pasireotide s.c or LAR at screening were eligible as long as they met protocol criteria during the screening period. If previously normo-glycemic participants experienced an increase in their fasting blood glucose and met the criteria for diabetes while on pasireotide, they started anti-diabetic treatment using metformin. If they continued to have elevated blood glucose above target on metformin within the first 16 weeks, they were randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks. Participants who continued to receive clinical benefit after completing the Core Phase could enter an optional Extension Phase if pasireotide was not commercially available in their country or a local access program was not available to provide drug. Patients continued in the Extension Phase until the last participant randomized in the Core Phase completed 16 weeks of treatment post-randomization.

Conditions

  • Cushing's Disease
  • Acromegaly

Interventions

  • Pasireotide s.c.Drug

    Administered to Cushing's disease participants.

  • SitagliptinDrug

    Taken for approximately 16 weeks during the core study phase or until the drug was found not to be effective

  • LiraglutideDrug

    Participant switched to liraglutide if sitagliptin was found not to be effective.

  • InsulinDrug

    Participant took insulin for 16 weeks. Insulin was also administered as rescue therapy in the incretin-based therapy arm if required. Insulin was administered to the BL-insulin group at the discretion of the Principal Investigator. Note: OAD and No OAD groups within the non-randomized arm did not take Insulin.

  • Pasireotide LARDrug

    Administered to Acromegaly participants.

  • MetforminDrug

    If previously normo-glycemic participants experienced increase in their fasting blood glucose and meeting the criteria for diabetes while on pasireotide, they started anti-diabetic treatment using metformin. If they continued to experience increase in their fasting blood glucose within the first 16 weeks, they were randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks. Metformin treatment was not required for the BL Insulin and OAD groups, within the non-randomized arm, but may have been prescribed at the discretion of the investigator. Note: No OAD group within the non-randomized arm did not take metformin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1c From Randomization to Approximately 16 WeeksTime frame: Randomization, 16 weeks

Locations

43 sites in 12 countries. Site status is shown where the registry gives one.

  • Diabetes and Endocrine Associates La Mesa Location

    Multiple Locations, California

  • LA Biomedical Research at Harbor UCLA Medical Center SC - SOM230B2219

    Torrance, California

  • Coastal Metabolic Research Centre SC

    Ventura, California

  • East Coast Institute for Research East Coast Inst. for Res(ECIR)

    Jacksonville, Florida

  • Washington University SC - SOM230B2411

    St Louis, Missouri

  • Great Falls Clinic

    Great Falls, Montana

  • Robert Wood Johnson Medical School - Rutgers SC

    New Brunswick, New Jersey

  • The Mount Sinai Hospital SC

    New York, New York

  • Columbia University Medical Center New York Presbyterian Neuroendocrine Unit

    New York, New York

  • Lenox Hill Hospital/Manhattan Eye, Ear and Throat Hospital SC

    New York, New York

  • Allegheny Endocrinology Associates SC

    Pittsburgh, Pennsylvania

  • Vanderbilt Clinical Trials Center SOM230B2219

    Nashville, Tennessee

  • Baylor College of Medicine Ben Taub General Hosp.

    Houston, Texas

  • Virginia Endocrinology Research SC-2

    Chesapeake, Virginia

  • Swedish Medical Center Dept.ofSeattle Neuroscience(2)

    Seattle, Washington

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Wilrijk, Belgium

  • Novartis Investigative Site

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site

    Joinville, Santa Catarina, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Beijing, Beijing Municipality, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, China

  • Novartis Investigative Site

    Chengdu, Sichuan, China

  • Novartis Investigative Site

    Aalborg, Denmark

  • Novartis Investigative Site

    Aarhus, Denmark

  • Novartis Investigative Site

    Herlev, Denmark

  • Novartis Investigative Site

    Odense C, Denmark

  • Novartis Investigative Site

    Erlangen, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, Germany

  • Novartis Investigative Site

    Oldenburg, Germany

  • Novartis Investigative Site

    Bangalore, Karnataka, India

  • Novartis Investigative Site

    Vellore, Tamil Nadu, India

  • Novartis Investigative Site

    San Isidro, Lima region, Peru

  • Novartis Investigative Site

    Warsaw, Poland

  • Novartis Investigative Site

    Wroclaw, Poland

  • Novartis Investigative Site

    Saint Petersburg, Russia

  • Novartis Investigative Site

    Bangkok, Thailand

  • Novartis Investigative Site

    Bangkok, Thailand

  • Novartis Investigative Site

    Songkhla, Thailand

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.